These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 29627897)

  • 1. Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters.
    Katsube T; Miyazaki S; Narukawa Y; Hernandez-Illas M; Wajima T
    Eur J Clin Pharmacol; 2018 Jul; 74(7):931-938. PubMed ID: 29627897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions.
    Stopfer P; Giessmann T; Hohl K; Hutzel S; Schmidt S; Gansser D; Ishiguro N; Taub ME; Sharma A; Ebner T; Müller F
    Br J Clin Pharmacol; 2018 Sep; 84(9):1941-1949. PubMed ID: 29665130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin.
    Stopfer P; Giessmann T; Hohl K; Sharma A; Ishiguro N; Taub ME; Zimdahl-Gelling H; Gansser D; Wein M; Ebner T; Müller F
    Clin Pharmacol Ther; 2016 Sep; 100(3):259-67. PubMed ID: 27256812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
    Ebner T; Ishiguro N; Taub ME
    J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
    Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
    J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
    Ogasawara K; Wood-Horrall RN; Thomas M; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):941-952. PubMed ID: 34477937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma t Antagonist, Bevurogant) on the Pharmacokinetics of a Transporter Probe Cocktail, Including Digoxin, Furosemide, Metformin, and Rosuvastatin: An Open-Label, Non-randomized, 2-Period Fixed-Sequence Trial in Healthy Subjects.
    Choi H; Huang F; Flack M
    Clin Pharmacol Drug Dev; 2024 Feb; 13(2):197-207. PubMed ID: 37960990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail.
    Stopfer P; Giessmann T; Hohl K; Sharma A; Ishiguro N; Taub ME; Jungnik A; Gansser D; Ebner T; Müller F
    Eur J Drug Metab Pharmacokinet; 2018 Feb; 43(1):69-80. PubMed ID: 28685495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
    Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
    Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects.
    Saisho Y; Katsube T; White S; Fukase H; Shimada J
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of drug-drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling.
    Chang M; Bathena S; Christopher LJ; Shen H; Roy A
    Cancer Chemother Pharmacol; 2022 Mar; 89(3):383-392. PubMed ID: 35147740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo.
    Song IS; Kong TY; Jeong HU; Kim EN; Kwon SS; Kang HE; Choi SZ; Son M; Lee HS
    BMC Complement Altern Med; 2014 Jul; 14():251. PubMed ID: 25034211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results From Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3.
    Heinig R; Fricke R; Wertz S; Nagelschmitz J; Loewen S
    Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):803-815. PubMed ID: 36029368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
    Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
    Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites.
    Zhou X; Zhang F; Chen C; Guo Z; Liu J; Yu J; Xu Y; Zhong D; Jiang H
    Xenobiotica; 2017 Mar; 47(3):267-275. PubMed ID: 27174018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Cefiderocol, a Siderophore Cephalosporin, on QT/QTc Interval in Healthy Adult Subjects.
    Sanabria C; Migoya E; Mason JW; Stanworth SH; Katsube T; Machida M; Narukawa Y; Den Nagata T
    Clin Ther; 2019 Sep; 41(9):1724-1736.e4. PubMed ID: 31378318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin.
    Johnson M; Patel D; Matheny C; Ho M; Chen L; Ellens H
    Drug Metab Dispos; 2017 Jan; 45(1):27-34. PubMed ID: 27737931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction.
    Müller F; Pontones CA; Renner B; Mieth M; Hoier E; Auge D; Maas R; Zolk O; Fromm MF
    Eur J Clin Pharmacol; 2015 Jan; 71(1):85-94. PubMed ID: 25552403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir.
    Kosloski MP; Bow DAJ; Kikuchi R; Wang H; Kim EJ; Marsh K; Mensa F; Kort J; Liu W
    J Pharmacol Exp Ther; 2019 Aug; 370(2):278-287. PubMed ID: 31167814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
    Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
    Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.